BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia | MicrobiomeTrials
BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2021-02-17Est. Completion: 2024-11-27
Enrollment target: 49 participants
Locations
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
Yale University, New Haven, Connecticut, United States
Mayo Clinic in Florida, Jacksonville, Florida, United States
Northwestern University, Chicago, Illinois, United States
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire, United States
Wake Forest University at Clemmons, Clemmons, North Carolina, United States
Wake Forest Baptist Health - Wilkes Medical Center, Wilkesboro, North Carolina, United States
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
VCU Massey Comprehensive Cancer Center, Richmond, Virginia, United States
Other microbiome trials you might be interested in